vascular biogenics ltd. is a biotechnology company located in 6yonatan netanyahu street, yehud, center district, israel.
Company profile
Ticker
NTBL
Exchange
Website
CEO
Dror Harats
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Vascular Biogenics Ltd.
SEC CIK
Corporate docs
Subsidiaries
VBL, Inc. • Notable Labs, Inc. • Notable Therapeutics, Inc. ...
NTBL stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
19 Apr 24
8-K
Notable Labs Reports 2023 Financial Results and Provides a Business Update
12 Apr 24
10-K
2023 FY
Annual report
11 Apr 24
8-K
Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024
9 Apr 24
8-K
Other Events
8 Apr 24
NT 10-K
Notice of late annual filing
1 Apr 24
8-K
Submission of Matters to a Vote of Security Holders
25 Mar 24
8-K
Changes in Registrant's Certifying Accountant
21 Mar 24
8-K
Other Events
22 Feb 24
DEF 14A
Definitive proxy
16 Feb 24
Transcripts
NTBL
Earnings call transcript
2022 Q1
17 May 22
NTBL
Earnings call transcript
2021 Q4
23 Mar 22
NTBL
Earnings call transcript
2021 Q3
15 Nov 21
NTBL
Earnings call transcript
2021 Q2
16 Aug 21
NTBL
Earnings call transcript
2021 Q1
11 May 21
NTBL
Earnings call transcript
2020 Q4
25 Mar 21
NTBL
Earnings call transcript
2020 Q3
16 Nov 20
NTBL
Earnings call transcript
2020 Q2
13 Aug 20
NTBL
Earnings call transcript
2020 Q1
14 May 20
NTBL
Earnings call transcript
2019 Q4
19 Mar 20
Latest ownership filings
4
Peter Feinberg
26 Jan 24
4
Tuomo Patsi
26 Jan 24
4
Michele Galen
26 Jan 24
4
Thomas Graney
26 Jan 24
4
THOMAS I H DUBIN
26 Jan 24
4
YEHUDA MICHAEL RICE
26 Jan 24
SC 13G/A
FR Capital Holdings, L.P.
11 Jan 24
4
Change in insider ownership
3 Jan 24
4
Change in insider ownership
2 Jan 24
4
Change in insider ownership
28 Dec 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 20.77 mm | 20.77 mm | 20.77 mm | 20.77 mm | 20.77 mm | 20.77 mm |
Cash burn (monthly) | 1.17 mm | (no burn) | 334.67 k | 662.83 k | 1.20 mm | 1.20 mm |
Cash used (since last report) | 7.93 mm | n/a | 2.28 mm | 4.51 mm | 8.14 mm | 8.14 mm |
Cash remaining | 12.84 mm | n/a | 18.49 mm | 16.26 mm | 12.62 mm | 12.62 mm |
Runway (months of cash) | 11.0 | n/a | 55.3 | 24.5 | 10.5 | 10.5 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 18 |
Opened positions | 7 |
Closed positions | 3 |
Increased positions | 1 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 162.78 mm |
Total shares | 9.39 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Aurum Ventures M.K.I. | 6.84 mm | $13.47 mm |
Slager David Mark | 1.81 mm | $2.38 mm |
MS Morgan Stanley | 327.01 k | $75.21 mm |
Group One Trading | 127.29 k | $29.28 mm |
VIRT Virtu Financial | 79.89 k | $18.00 k |
Geode Capital Management | 40.32 k | $9.27 mm |
Catalyst Financial Partners | 39.00 k | $8.97 mm |
Two Sigma Investments | 32.90 k | $7.57 mm |
Advisor | 22.49 k | $5.20 mm |
HBK Sorce Advisory | 20.58 k | $4.73 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
24 Jan 24 | Yehuda Michael Rice | Stock Option Ordinary Shares | Grant | Acquire A | No | No | 1.28 | 6,534 | 8.36 k | 6,534 |
24 Jan 24 | Thomas I H Dubin | Stock Option Ordinary Shares | Grant | Acquire A | No | No | 1.28 | 9,753 | 12.48 k | 9,753 |
24 Jan 24 | Michele Galen | Stock Option Ordinary Shares | Grant | Acquire A | No | No | 1.28 | 9,753 | 12.48 k | 9,753 |
24 Jan 24 | Thomas Graney | Stock Option Ordinary Shares | Grant | Acquire A | No | No | 1.28 | 9,753 | 12.48 k | 9,753 |
24 Jan 24 | Peter Feinberg | Stock Option Ordinary Shares | Grant | Acquire A | No | No | 1.28 | 9,753 | 12.48 k | 9,753 |
News
JMP Securities Reiterates Market Outperform on Notable Labs, Maintains $9 Price Target
15 Apr 24
Cisco To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Monday
15 Apr 24
Chardan Capital Maintains Buy on Notable Labs, Lowers Price Target to $7
15 Apr 24
Notable Labs Presents The Design Plan For PPMP-Enabled Phase 2 Trial With Volasertib For Relapsed/Refractory AML At AACR 2024
9 Apr 24
Notable Labs Presentation Of Data Related To Innovations In The Use Of Cryopreserved Samples In The PPMP Assay At AACR 2024 Expands The Potential Of The Platform
8 Apr 24
Press releases
Notable Labs Reports 2023 Financial Results and Provides a Business Update
12 Apr 24
Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024
9 Apr 24
Notable Labs Presentation of Data Related to Innovations in the Use of Cryopreserved Samples in the PPMP Assay at AACR 2024 Expands the Potential of the Platform
8 Apr 24
Notable Labs to Present Two Posters at AACR 2024 on PPMP Platform
5 Mar 24